LivaNova LIVN Cardiopulmonary — Cost of Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by LivaNova in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about LivaNova's cardiopulmonary — cost of sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is LivaNova's cardiopulmonary — cost of sales?
- LivaNova (LIVN) reported cardiopulmonary — cost of sales of $100.93M in Q1 2026.
- How has LivaNova's cardiopulmonary — cost of sales changed year-over-year?
- LivaNova's cardiopulmonary — cost of sales increased by 18.9% year-over-year, from $84.92M to $100.93M.
- What is the long-term trend for LivaNova's cardiopulmonary — cost of sales?
- Over 3 years (2022 to 2025), LivaNova's cardiopulmonary — cost of sales has grown at a 14.9% compound annual growth rate (CAGR), from $251.86M to $381.71M.
- What does cardiopulmonary — cost of sales mean?
- Includes the direct costs attributable to the production of goods sold by the cardiopulmonary segment, such as raw materials and direct labor. Monitoring this metric helps assess manufacturing efficiency and the impact of input cost fluctuations on gross margins.